UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On March 29, 2024, Dynavax Technologies Corporation (the “Company”) appointed Ryan Spencer to serve in a temporary capacity as Interim Chief Financial Officer (principal financial officer) of the Company while Kelly MacDonald is on maternity leave, commencing April 1, 2024. Ms. MacDonald is expected to return in early August 2024, at which time Ms. MacDonald will resume her role as Chief Financial Officer (principal financial officer) of the Company. During Ms. MacDonald’s absence, other officers of the Company have assumed certain of Ms. MacDonald’s duties while remaining in their current positions, with the addition of a senior-level consultant with public company Chief Financial Officer experience.
Mr. Spencer currently also serves as the Company’s Chief Executive Officer and as a member of the Board. There will be no change in Mr. Spencer’s compensation as a result of this appointment. Biographical information for Mr. Spencer is available in the Company’s proxy statement filed with the Securities and Exchange Commission on April 13, 2023 in connection with the Company’s 2023 annual meeting of stockholders, such information being incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Dynavax Technologies Corporation |
|
|
|
|
Date: |
April 1, 2024 |
By: |
/s/ Ryan Spencer |
|
|
|
Ryan Spencer |
Document And Entity Information |
Mar. 29, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Mar. 29, 2024 |
| Entity Registrant Name | Dynavax Technologies Corporation |
| Entity Central Index Key | 0001029142 |
| Entity Emerging Growth Company | false |
| Entity File Number | 001-34207 |
| Entity Incorporation, State or Country Code | DE |
| Entity Tax Identification Number | 33-0728374 |
| Entity Address, Address Line One | 2100 Powell Street, Suite 720 |
| Entity Address, City or Town | Emeryville |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94608 |
| City Area Code | 510 |
| Local Phone Number | 848-5100 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, $0.001 par value |
| Trading Symbol | DVAX |
| Security Exchange Name | NASDAQ |